Levosulpiride for the treatment of diabetic macular oedema: a phase 2 randomized clinical trial.

ABSTRACT:

Background/objective

The prokinetic levosulpiride elevates vasoinhibin levels in the vitreous of patients with proliferative diabetic retinopathy (PDR) suggesting clinical benefits due to the anti-vasopermeability and anti-angiogenic properties of vasoinhibin. We investigated the biological activity of levosulpiride in centre-involving diabetic macular oedema (DME).

Patients/methods

Prospective, randomized, double-blinded, dual-centre, phase 2 trial in patients with centre-involving DME orally treated with placebo (n = 17) or levosulpiride (n = 17) for 8 weeks or in patients with PDR undergoing elective pars plana vitrectomy and receiving placebo (n = 18) or levosulpiride (n = 18) orally for the 1 week before vitrectomy.

Results

Levosulpiride improved changes from bas

SUBMITTER: Nunez-Amaro CD 

PROVIDER: S-EPMC10858020 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature